Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O’Day, Michael Onuscheck, Jon Snyder

Premium
The California Healthcare Institute said this week that it has elected Daniel O’Day and Michael Onuscheck to its board of directors.
 
O’Day is currently president and CEO at Roche Molecular Diagnostics in Pleasanton, Calif. Onuscheck is president of the neuromodulation division at Boston Scientific.
 
CHI is a non-profit public-policy research organization representing California’s academic institutions, and biotechnology, medical device, diagnostics, and pharmaceutical firms.
 

 
Arboretum Ventures, headquartered in Ann Arbor, Mich., said this week that it has opened an office at the BioEnterprise facility in Cleveland, and named Jon Snyder manager.
 
Snyder is joining Arboretum as a venture partner from BioEnterprise, where he was worked since January as CEO in residence.
 
Arboretum Ventures is an early-stage venture capital firm focusing on investments in medical technology and healthcare services.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.